AIM ImmunoTech is trading at $0.27, down -5.01% in a speculative, technically driven move.
- The decline reverses part of its 7.83% gain from August 5, 2026, with no confirmed company-specific catalyst.
- Biotech sentiment remains positive, with XBI reportedly up 2.09%, making sector weakness an unlikely explanation.
- A filing-related report noted termination of the Maxim equity-distribution agreement and prior share sales, but no reliable source directly links it to today’s decline.